284 related articles for article (PubMed ID: 20220057)
21. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy.
Mohammad G; Kowluru RA
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3832-41. PubMed ID: 21345984
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine Disrupts Balance between MMP-9 and Its Tissue Inhibitor in Diabetic Retinopathy: The Role of DNA Methylation.
Mohammad G; Kowluru RA
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150828
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier.
Giebel SJ; Menicucci G; McGuire PG; Das A
Lab Invest; 2005 May; 85(5):597-607. PubMed ID: 15711567
[TBL] [Abstract][Full Text] [Related]
25. TIAM1-RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy.
Kowluru RA; Kowluru A; Veluthakal R; Mohammad G; Syed I; Santos JM; Mishra M
Diabetologia; 2014 May; 57(5):1047-56. PubMed ID: 24554007
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction.
Mohammad G; Kowluru RA
Lab Invest; 2010 Sep; 90(9):1365-72. PubMed ID: 20479714
[TBL] [Abstract][Full Text] [Related]
27. Aquaporin 4 knockdown exacerbates streptozotocin-induced diabetic retinopathy through aggravating inflammatory response.
Cui B; Sun JH; Xiang FF; Liu L; Li WJ
Exp Eye Res; 2012 May; 98():37-43. PubMed ID: 22449442
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes.
Miyahara S; Kiryu J; Yamashiro K; Miyamoto K; Hirose F; Tamura H; Katsuta H; Nishijima K; Tsujikawa A; Honda Y
Am J Pathol; 2004 May; 164(5):1697-706. PubMed ID: 15111316
[TBL] [Abstract][Full Text] [Related]
29. Loss of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) in the Diabetic Retina: Role of Matrix Metalloproteinases.
Eshaq RS; Harris NR
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):748-760. PubMed ID: 30793207
[TBL] [Abstract][Full Text] [Related]
30. Diabetic eNOS-knockout mice develop accelerated retinopathy.
Li Q; Verma A; Han PY; Nakagawa T; Johnson RJ; Grant MB; Campbell-Thompson M; Jarajapu YP; Lei B; Hauswirth WW
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5240-6. PubMed ID: 20435587
[TBL] [Abstract][Full Text] [Related]
31. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Diabetes-Induced Lysyl Oxidase Overexpression Prevents Retinal Vascular Lesions Associated With Diabetic Retinopathy.
Song B; Kim D; Nguyen NH; Roy S
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5965-5972. PubMed ID: 30550614
[TBL] [Abstract][Full Text] [Related]
33. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy.
Kowluru RA; Santos JM; Zhong Q
Invest Ophthalmol Vis Sci; 2014 Jun; 55(9):5653-60. PubMed ID: 24894401
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of Lysyl Oxidase Protects Retinal Endothelial Cells From High Glucose-Induced Apoptosis.
Kim D; Mecham RP; Trackman PC; Roy S
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2725-2731. PubMed ID: 28538980
[TBL] [Abstract][Full Text] [Related]
35. The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage.
Kim SR; Im JE; Jeong JH; Kim JY; Kim JT; Woo SJ; Sung JH; Park SG; Suh W
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1201-6. PubMed ID: 26978025
[TBL] [Abstract][Full Text] [Related]
36. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of retinal GLUT1 in diabetes by ubiquitinylation.
Fernandes R; Carvalho AL; Kumagai A; Seica R; Hosoya K; Terasaki T; Murta J; Pereira P; Faro C
Mol Vis; 2004 Aug; 10():618-28. PubMed ID: 15359219
[TBL] [Abstract][Full Text] [Related]
38. Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.
Ottlecz A; Bensaoula T
Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1633-41. PubMed ID: 8675407
[TBL] [Abstract][Full Text] [Related]
39. Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats.
Yang C; Zhu P; Yan L; Chen L; Meng R; Lao G
J Am Podiatr Med Assoc; 2009; 99(6):489-96. PubMed ID: 19917734
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.
Kowluru RA; Zhong Q; Santos JM
Expert Opin Investig Drugs; 2012 Jun; 21(6):797-805. PubMed ID: 22519597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
